NASDAQ · Biotechnology

Merrimack Pharmaceuticals, Inc. (MACK) Stock

$15.15 +0.10% NASDAQ: MACK Healthcare

Founded in 1993, Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts.

Valuation

MetricValue
Price$15.15
Market Cap$223.97M
P/E Ratio-183.35
P/B Ratio11.55
P/S Ratio0.00
EPS (TTM)$-0.08
52-Week High$15.89
52-Week Low$11.53
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-6.22%
ROA-6.15%
ROCE-11.61%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio43.50

Annual Financials (USD)

Metric20192020202120222023
Revenue$0$0$0$0$0
Operating Profit$-22.0M$-3.0M$-2.0M$-2.0M$-2.0M
Net Profit$-21.0M$-3.0M$-2.0M$-2.0M$-1.0M
EPS$-1.59$-0.23$-0.18$-0.11$-0.08
Op Margin—————

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$20.0M$17.0M$15.0M$20.0M$19.0M
Total Liabilities$3.0M$1.0M$1.0M$1.0M$0
Cash$17.0M$14.0M$14.0M$19.0M$6.0M
Borrowings$0$0$0$0$0

Latest News

NYLI MacKay DefinedTerm Muni Opportunities Fund Declares Monthly Dividend Distributions for the Months of July, August, and September 2026 Business Wire · Jul 1, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-31.0M$-5.0M$0$-2.0M$-2.0M
Investing Cash Flow$70.0M$2.0M$0$0$-12.0M
Financing Cash Flow$-16.0M$0$0$7.0M$1.0M
Net Cash Flow$-4.0M$-3.0M$0$5.0M$-13.0M
Free Cash Flow$-31.0M$-5.0M$0$-2.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.06
EV / EBITDA216.47
FCF Yield-0.68%
Quick Ratio43.50
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CATB $8.54 -6.97% -5.02 $234.86M 0.00%
CBLICytocom, Inc. $3.17 -7.31% -16.68 $226.39M 0.00%
CRGXCARGO Therapeutics, Inc. Common Stock $4.47 +0.00% -1.59 $216.19M 0.00%
INXBInhibrx Biosciences, Inc. $15.86 +13.94% -10.29 $225.87M 0.00%
SLRNAcelyrin, Inc. $2.27 +0.00% -0.91 $229.17M 0.00%

About Merrimack Pharmaceuticals, Inc.

Founded in 1993, Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals, Inc. is headquartered in US.

Merrimack Pharmaceuticals, Inc. (MACK) stock trades at $15.15 with a market capitalization of $223.97M. The stock is valued at a price-to-earnings (P/E) ratio of -183.35, price-to-book of 11.55, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $11.53 and $15.89, and currently trades 4.7% below its 52-week high.

On profitability, Merrimack Pharmaceuticals, Inc. generates a return on equity (ROE) of -6.22%, return on capital employed of -11.61%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.merrimack.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides